Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Jul;94(3):933–937. doi: 10.1111/j.1476-5381.1988.tb11606.x

Perinatal lead exposure alters the development of delta- but not mu-opioid receptors in rat brain.

J McDowell 1, I Kitchen 1
PMCID: PMC1854035  PMID: 2846111

Abstract

1. Low level lead exposure has been shown to impair the development of opioid peptide levels in the brain, and to impair antinociceptive responses to opioid drugs. We have now studied the effects of lead exposure on the development of opioid receptors using ligand binding studies. 2. The ontogenesis of mu- and delta-opioid binding sites was studied using rat whole brain membranes and [3H]-[D-Ala2MePhe4-Gly-ol]enkephalin and [3H]-[D-Pen2,D-Pen5]enkephalin as binding ligands. Rats were exposed to lead during development by addition of lead acetate (at 100-1000 p.p.m.) to the maternal drinking water from conception to postnatal day 14. 3. Perinatal lead exposure had no significant effects on the binding affinity (KD) or binding capacity (Bmax) for the mu-opioid receptor measured at postnatal days 10, 21 and 30. Lead exposure (at 1000 p.p.m.) increased the KD for the delta-opioid receptor at postnatal days 15, 21, 35 and 50 but had no effect on the binding capacity. No indications of overt toxicity were observed and blood lead levels were in the ranges considered to represent subclinical lead toxicity in man. 4. The lack of effect of lead on mu-receptor binding contrasts with previously described impairment of antinociceptive effects of mu-agonists suggesting that the toxicity is not manifested at the mu-binding site. However, the delta-opioid receptor appears to be more sensitive to lead exposure and the persistent changes in delta-site affinity after cessation of lead exposure suggest irreversible damage in the production of the receptor protein.

Full text

PDF
933

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey C. C., Kitchen I. Ontogeny of catecholamine and GABA levels in rat brain: lack of effect of perinatal lead exposure. Toxicol Lett. 1986 Jan;30(1):97–102. doi: 10.1016/0378-4274(86)90184-0. [DOI] [PubMed] [Google Scholar]
  2. Bailey C., Kitchen I. Ontogenesis of proenkephalin products in rat striatum and the inhibitory effects of low-level lead exposure. Brain Res. 1985 Sep;354(1):75–79. doi: 10.1016/0165-3806(85)90070-7. [DOI] [PubMed] [Google Scholar]
  3. Baraldi M., Zanoli P., Rossi T., Borella P., Caselgrandi E., Petraglia F. Neurobehavioral and neurochemical abnormalities of pre- and postnatally lead-exposed rats: zinc, copper and calcium status. Neurobehav Toxicol Teratol. 1985 Sep-Oct;7(5):499–509. [PubMed] [Google Scholar]
  4. Barrett J., Livesey P. J. Low level lead effects on activity under varying stress conditions in the developing rat. Pharmacol Biochem Behav. 1985 Jan;22(1):107–118. doi: 10.1016/0091-3057(85)90493-9. [DOI] [PubMed] [Google Scholar]
  5. Barrett J., Livesey P. J. The acetic acid component of lead acetate: its effect on rat weight and activity. Neurobehav Toxicol Teratol. 1982 Jan-Feb;4(1):105–108. [PubMed] [Google Scholar]
  6. Carmichael N. G., Winder C., Lewis P. D. Dose response relationships during perinatal lead administration in the rat: a model for the study of lead effects on brain development. Toxicology. 1981;21(2):117–128. doi: 10.1016/0300-483x(81)90122-0. [DOI] [PubMed] [Google Scholar]
  7. Gillan M. G., Kosterlitz H. W. Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain. Br J Pharmacol. 1982 Nov;77(3):461–469. doi: 10.1111/j.1476-5381.1982.tb09319.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kitchen I., McDowell J. Impairment of ketocyclazocine antinociception in rats by perinatal lead exposure. Toxicol Lett. 1985 Aug;26(2-3):101–105. doi: 10.1016/0378-4274(85)90152-3. [DOI] [PubMed] [Google Scholar]
  9. Kitchen I., McDowell J., Winder C., Wilson J. M. Low-level lead exposure alters morphine antinociception in neonatal rats. Toxicol Lett. 1984 Aug;22(2):119–123. doi: 10.1016/0378-4274(84)90054-7. [DOI] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. McDowell J., Kitchen I. Ontogenesis of delta-opioid receptors in rat brain using [3H][D-Pen2,D-Pen5]enkephalin as a binding ligand. Eur J Pharmacol. 1986 Sep 9;128(3):287–289. doi: 10.1016/0014-2999(86)90780-6. [DOI] [PubMed] [Google Scholar]
  12. Paterson S. J., Robson L. E., Kosterlitz H. W. Classification of opioid receptors. Br Med Bull. 1983 Jan;39(1):31–36. doi: 10.1093/oxfordjournals.bmb.a071787. [DOI] [PubMed] [Google Scholar]
  13. Spain J. W., Roth B. L., Coscia C. J. Differential ontogeny of multiple opioid receptors (mu, delta, and kappa). J Neurosci. 1985 Mar;5(3):584–588. doi: 10.1523/JNEUROSCI.05-03-00584.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Winder C., Kitchen I. Lead neurotoxicity: a review of the biochemical, neurochemical and drug induced behavioural evidence. Prog Neurobiol. 1984;22(1):59–87. doi: 10.1016/0301-0082(84)90018-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES